Wordt geladen...
Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
Over the last few years, dramatic changes have occurred in the treatment of chronic lymphocytic leukemia (CLL). The current standard for young and fit patients with CLL remains chemoimmunotherapy, namely the fludarabine, cyclophosphamide, and rituximab (FCR) regimen. However, novel oral therapies ar...
Bewaard in:
| Gepubliceerd in: | Onco Targets Ther |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5308588/ https://ncbi.nlm.nih.gov/pubmed/28223822 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S102646 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|